Low molecular weight heparin in pregnancy: current issues.
about
Diagnosis and treatment of deep-vein thrombosisPerinatal stroke--risk factors and management.The management of Cesarean delivery in a parturient with paroxysmal nocturnal hemoglobinuria complicated by severe preeclampsia.Enoxaparin use in pregnancy: state of the art.Leveraging physiological data from literature into a pharmacokinetic model to support informative clinical study design in pregnant women.Pharmacokinetics, efficacy, and safety of LMWHs in venous thrombosis and stroke in neonates, infants and childrenThromboembolic events in pregnancy: pharmacological prophylaxis and treatment.The presence of heparins during decidualization modulates the response of human endometrial stromal cells to IL-1β in vitro.Diagnosis and treatment of deep-vein thrombosis and approach to venous thromboembolism in obstetrics and gynecologyReview: Low-molecular-weight heparin-induced osteoporosis and osteoporotic fractures: a myth or an existing entity?Anticoagulant and antithrombotic drugs in pregnancy: what are the anesthetic implications for labor and cesarean delivery?In vitro evidences of heparin's effects on embryo implantation and trophoblast development.Pregnancy-associated venous thrombosis.Chirurgische Behandlung von Melanomen in der Schwangerschaft: eine praktische Anleitung.Surgical treatment of melanoma in pregnancy: a practical guideline.Adjustment of therapeutic LMWH to achieve specific target anti-FXa activity does not affect outcomes in pregnant patients with venous thromboembolism.Outcome of pregnancies in women with thrombophilic disorders.The effects of antenatal anticoagulants (low-molecular-weight heparin and aspirin) on neonatal pulmonary vasculature in rabbits.Fluctuations in anti-factor Xa levels with therapeutic enoxaparin anticoagulation in pregnancy.Birthweight in pregnant women with protein S deficiency treated with low-molecular-weight heparin: a retrospective cohort study.Women's views on and adherence to low-molecular-weight heparin therapy during pregnancy and the puerperium.Low-molecular-weight heparin in pregnancy: state of the art.
P2860
Q24673847-48EA3335-7F82-4E5F-AF97-C903D67C996EQ30996238-7A422D1A-585A-474F-8295-990573360725Q33376085-E7D8B193-1E15-45D3-B6AA-747C225F9A00Q33386499-F7CA6425-10F0-40DD-913B-4D611065A918Q34127900-E4EEC93C-FFE3-4285-A7FD-EAAAE9FD994EQ36510063-1CC93B00-01F6-4179-B8F7-6F2828DCF39EQ37000726-E3EF065E-F59E-4E1F-A828-95E942B38005Q37059967-9E2B9401-5B18-418B-B5D0-8227100ACB98Q37611378-B1F287AA-2F96-44F0-8ABA-2D1253748B46Q37637677-4E994E06-977D-4BC7-8042-18F41B642E3CQ37766083-8404E5FC-AE5F-4CBA-81FA-B7F90BBECBAEQ37989428-ACC7EC5A-3F1D-4704-BA52-BBE28A673686Q37998007-9DE51749-3749-44A7-89D6-854DA07D2C4BQ38848123-3561E6EF-1D09-4F9A-A8CC-33133E9184EAQ38848127-DA2AEC35-2C4B-4D64-8713-F2EE26E1F25FQ39496163-CFEE6BFC-EA3C-45C4-9731-C415CCD57D70Q42787440-49C8547F-F316-432D-A720-3AFA86DCF312Q43227978-243F20F4-D9DD-4637-A177-6D0044E1F91BQ43261332-571461B8-99A4-4056-8310-1072C87692E5Q47271143-02413239-20FE-4D3A-B2A2-D4E773B45BCEQ47280594-58E57B9F-988E-448D-BAC7-D22EA813331DQ47370577-E0975DBB-0C76-4DBF-9899-0E4C21A8C1A5
P2860
Low molecular weight heparin in pregnancy: current issues.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Low molecular weight heparin in pregnancy: current issues.
@ast
Low molecular weight heparin in pregnancy: current issues.
@en
type
label
Low molecular weight heparin in pregnancy: current issues.
@ast
Low molecular weight heparin in pregnancy: current issues.
@en
prefLabel
Low molecular weight heparin in pregnancy: current issues.
@ast
Low molecular weight heparin in pregnancy: current issues.
@en
P2860
P1476
Low molecular weight heparin in pregnancy: current issues.
@en
P2093
Beverley J Hunt
P2860
P304
P356
10.1111/J.1365-2141.2004.05304.X
P407
P577
2005-03-01T00:00:00Z